RESEARCHER PROFILE
Dr Laura Klein, National Milk Research Leader
Australian Red Cross Lifeblood,
New South Wales
Australia
Dr Laura Klein is National Milk Research Leader at Australian Red Cross Lifeblood. Australian Red Cross Lifeblood is funded by Australian governments to provide life-giving blood, plasma, and transplantation and biological products.
Dr Klein works with clinicians and researchers across Australia to understand how donated breast milk can be used to improve outcomes for vulnerable babies. She’s passionate about generating evidence to improve the products and services that milk banks provide to donors and the families who receive donated breast milk.
Dr Klein has a PhD from Harvard University and is an Adjunct Research Associate in the Faculty of Pharmacy and Pharmaceutical Sciences at Monash University.
Australian Red Cross Lifeblood national milk service has already closed the gap in helping very preterm babies (born less than 32 weeks’ gestation) access donated breast milk. Currently they supply milk to more than 1,000 babies every year across New South Wales, South Australia, Queensland, and Tasmania.
Dr Klein is currently conducting Australian-first research that could potentially help thousands of babies in the future. Together with the University of Adelaide and South Australian Institute of Health and Medical Research Institute (SAHMRI), Australian Red Cross Lifeblood is conducting a randomised controlled trial at five sites in three states. exploring how donated breast milk may benefit babies born later than 32 weeks gestation when the mother’s own breast milk is unavailable.
Babies born 4 to 6 weeks before their due date (moderate to late preterm) often have trouble feeding and most need extra nutrition while breastfeeding is established.
Infant formula is regularly used as additional nutrition for pre-term babies, but it can contribute to complications, including feeding intolerance, increased need for IV fluids, interrupted breastfeeding, effects on weight gain and delayed hospital discharge.
Human milk is easier to digest than formula and protects babies against other serious diseases and infections. It has all the nutrients babies need for their growth and development.
In the trial, more than 2000 pre-term babies will participate in a donor breast milk trial funded by National Health and Medical Research Council (NHMRC) Clinical Trials and Cohort Studies (CTCS) Grants.
Mother’s own milk is a complex fluid shaped by interactions between a mum and her infant, while donated breast milk is something different. Donated breastmilk is a precious gift that can improve outcomes for premature infants, but it is not the same as mother’s own milk.
“Donated breast milk is the World Health Organisation’s recommendation for infant feeding when a mother’s own breast milk is unavailable, because of its association with improved breastfeeding rates and protective properties,” says Dr Laura Klein.
“Our research will aim to explore other benefits for infants and their families, including reducing allergies during the first year of life. There’s little research to inform the use of donor milk in babies born after 32 weeks.”
Outside of work, she enjoys going for bike rides, doing yoga, and exploring different places around Australia. Having moved to Australia from the United States in 2019, she looks forward to seeing parts of Australia, she hasn’t yet seen.
SEE OTHER RESEARCHER PROFILES
Bench Side Story
www.benchsidestory.com
-
Healthcare associated infection prevention
Professor Philip Russo is an internationally regarded expert in healthcare associated infection prevention, and led the recently completed the Australian National Healthcare Associated Infection Point Prevalence Survey, the first in Australia for 34 years. He is also Past President of the Australasian College for Infection Prevention and Control (ACIPC), the peak body for Infection Prevention and Control professionals in the Australasian region.
-
Neonatal respiratory trials in sick & preterm newborn infants
Prof Brett J. Manley leads and collaborates on large national and international randomised clinical trials in neonatology. He previously collaborated on 4 randomised trials of nasal high-flow as non-invasive respiratory support for preterm and term infants, all of which were published in N Engl J Med. Recently he led the PLUSS trial of intratracheal budesonide for extremely preterm infants, that recruited in 21 NICUs across 4 countries, the results of which were published in JAMA. PLUSS was awarded the Australian Clinical Trials Alliance Trial of the Year in 2025. Another passion of his is mentoring and supervising early career researchers to undertake their own clinical trials.
-
Stem cell therapies for enteric neuropathies
Dr Stamp is a Group Leader in the Department of Anatomy and Physiology at the University of Melbourne, Australia. Dr Stamp’s PhD research (with Prof Martin Pera, Monash University) focused on the derivation of hepatopancreatic progenitors from human embryonic stem cells. He then joined the lab of Dr Don Newgreen at the Murdoch Childrens Research Institute where he began working on development of the enteric nervous system (ENS), before joining Prof Heather Young’s lab at the University of Melbourne, where he focused on developing a stem cell therapy to treat gut motility disorders such as the paediatric enteric neuropathy Hirschprung disease.
